SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-035082
Filing Date
2024-03-15
Accepted
2024-03-15 17:22:28
Documents
15
Period of Report
2024-03-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm248952d1_8k.htm   iXBRL 8-K 30058
2 EXHIBIT 10.2 tm248952d1_ex10-2.htm EX-10.2 247492
  Complete submission text file 0001104659-24-035082.txt   516004

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20240315.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20240315_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20240315_pre.xml EX-101.PRE 22363
16 EXTRACTED XBRL INSTANCE DOCUMENT tm248952d1_8k_htm.xml XML 3718
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 24756057
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)